Alzheimer’s Disease | Access and Reimbursement | US | 2019
No novel pharmacotherapeutics have entered the AD market in more than 15 years, despite a perennially full pipeline. However, the potential launches of the first disease-modifying therapies (DMTs) to delay the progression of AD (e.g., Biogen/Neurimmune’s aducanumab, Roche/MorphoSys’s gantenerumab, and others), and the first approved symptomatics to treat AD agitation—all within the next five years—will fundamentally alter the dynamics of this market, driven by clear need, strong market demand, and assumed premium pricing. Understanding neurologists’ preferences for and expectations from new therapeutics, counterpoised by payers’ receptivity to high-cost brands entering a highly underserved but heavily generic market, will be key for pharmaceutical companies developing new drugs or considering entering this wide-open arena.
Questions answered
- What is the current state of coverage of key symptomatic therapies used to treat AD patients in the United States? What restrictions do payers impose, and how do market access dynamics influence surveyed neurologists’ prescribing?
- How receptive are payers to late-phase DMTs and new brands in development for the management of AD agitation? What coverage decisions do they anticipate? How do neurologists expect to prescribe the agents?
- What actions can developers take to optimize market access?
Product description
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Markets covered: United States
Primary research: Survey of 102 U.S. neurologists and 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
Key drugs covered: AChEIs, memantine, Namzaric, aducanumab, gantenerumab, antipsychotics, AVP-786, Rexulti
Content highlights
- Reimbursement and contracting.
- Access and prescribing.
- Special topics.
- Opportunities and challenges for emerging therapies.
